This is consistent with the known survival advantage conferred by STAT3 activation in CLL namely by upregulating expression of anti-apoptotic genes, enhancing the B-cell receptor (BCR) signaling, promoting interactions with the microenvironment, modulating the immune response and contributing to immune evasion [28, 29]. The gene discussed is STAT3; the disease is B-cell chronic lymphocytic leukemia.